Using Cotyledon Perfusion to Study Drugs Transfer Across the Placenta

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-05

Study Completion Date

2030-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Drug prescriptions are usual during pregnancy however women and their fetuses still remain an orphan population with regard to drugs efficacy and safety clinical studies. Most xenobiotics diffuse through the placenta and some of them can alter fetus development resulting in structural abnormalities, growth or functional deficiencies. The aim of the study is to study the drug transfer using human placenta after delivery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Longitudinal Study of Gene Expression in the Human Placenta During First-trimester and Full-term Pregnancy at the Single Cell Level

NCT06427408

Pregnancy Related

NOT_YET_RECRUITING

Transplacental Transfer of Drugs Used in Pregnant Women

NCT02622802

Pregnancy

COMPLETED NA

Placental Transfer of Sugammadex in the Human Placental Perfusion Model

NCT06634355

Pregnancy

ENROLLING_BY_INVITATION NA

Autophagy/Apoptosis Balance in Placental Vascular Pathologies

NCT06779916

Pregnancy Complications Pre-Eclampsia Growth Retardation, Intrauterine

RECRUITING

MRI Angiography of Physiological and Pathological Pregnancy Placentas Ex-vivo

NCT04389099

Pre-Eclampsia Fetal Growth Retardation

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

For ethical reasons, pregnant woman are not included in clinical trials so that data regarding safety and efficacy of many drugs are scarce. It is known that xenobiotics across the placental barrier but studies regarding quantity and mechanisms of this transfer remain insuffisant. Among the different methodologies to evaluate drug transfer, perfusion of human cotyledon is one of the most relevant ones. The two sides of the cotyledon, fetal and maternal ones, are perfused within the hour after delivery with EARLE medium in a double closed circuit. The studied drug (it can be any drug given to pregnant mothers) and antipyrine (the control molecule) are added at the beginning of the three hours perfusion realized at 37°C, with maternal flow rate of 12ml/min and fetal one of 6ml/min. Samples are collected along the perfusion and the drugs dosage will be done in the pharmacology department of Cochin Hospital. Tissues of the cotyledon will be also collected to study the proteins, and ARNs expressed. The drug concentrations will be analyzed by calculating fetal to maternal concentrations ratios and a fetal transfer rate (fetal drug quantity on total drug quantity at the end of the perfusion). Then modelling on Monolix software will be done to estimate the transfer constants across the two compartments. Modelling will allow to estimate the interindividual variability and to test covariables like sex, gestation duration, genetics, or protein expression. Proteins will be studied by an appropriated method (western blot, or proteomic analysis). The genetics study will consist in candidate gene approach. Polymorphisms will be chosen in genes coding for transporters or enzymes or their regulators.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Normal Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pregnant mothers

Pregnant mothers who have a normal pregnancy

Placenta perfusion

Intervention Type OTHER

Placenta perfusion in double closed circuit, during 3 hours

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placenta perfusion

Placenta perfusion in double closed circuit, during 3 hours

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* pregnant women older than 18 years,
* patient with social security or health insurance,
* from the 24th week of amenorrhea,
* patient who has given her consent,

Exclusion Criteria

* Maternal pathologies pre-existing pregnancy :

* diabetes-like vascular disease,
* arterial hypertension,
* known prothrombotic pathology, history of venous thrombosis or pulmonary embolism,
* maternal serology HIV+, BHV+, CHV+ and syphilis,
* Pregnancy and fetal pathologies :

* pre-eclampsia,
* delayed growth in utero (can affect placental circulation),
* gestational diabetes without insulin,
* fetal malformation,
* known genetic pathology,
* Patient under tutorship or curatorship, or not speaking french,
* Patient who has not given her consent

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No